Oramed Pharmaceuticals Inc. (ORMP) news stock charts
Oramed Pharmaceuticals Inc. (ORMP/ORMP.OB) Investment Summary:
Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals, Inc. in 2006. Oramed Pharmaceuticals is based in Jerusalem, Isra...ORAMED PHARMACEUTICALS INC (ORMP:OTC Bulletin Board Market)
Snapshot of ORAMED PHARMACEUTICALS INC (ORMP)
|
OPEN
$0.43
|
PREVIOUS CLOSE
$0.43
|
|
|
DAY HIGH
$0.43
|
DAY LOW
$0.43
|
|
|
52 WEEK HIGH
09/8/09 - $0.64
|
52 WEEK LOW
03/27/09 - $0.26
|
|
|
MARKET CAP
24.5M
|
AVERAGE VOLUME 10 D
9.5K
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
57.0M
|
|
|
ORMP Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ORAMED PHARMACEUTICALS INC (ORMP)
Oramed Pharmaceuticals Inc. announced that John M. Amatruda, M.D. has joined the company's Scientific Advisory Board, enhancing Oramed's talented and experienced scientific team. Dr. Amatruda was the Senior Vice President and Franchise Head, Diabetes and Obesity at Merck Research Laboratories. He is board certified in internal medicine, endocrinology and metabolism and has a proven track record in academics and pharmaceutical discovery research and development, including several novel candidate compounds, INDs, translational studies, development programs and four NDAs. In joining the Scientific Advisory Board, Dr. Amatruda will provide Oramed access to his extensive successful pharmaceutical industry experience in the development and approval of novel drugs. Additionally, his experience in licensing, structuring agreements and managing collaborations will prove invaluable to the company.
Oramed Pharmaceuticals Inc. Presents at Third International Conference on Advanced Technologies and Treatments for Diabetes in 2010, Feb-11-2010 through Feb-13-2010. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH - 4005 Basel, Swaziland. Speakers: Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director.
Oramed Pharmaceuticals Inc. announced the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients was enrolled for a study in which subjects will be administered the insulin-based capsule for a period of six weeks. The randomized, double-blind, placebo-controlled, multi-centered study will evaluate the safety, tolerability, and efficacy of Oramed's oral insulin delivery technology. The study is taking place in five locations throughout South Africa and is being monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa. Study results are expected by the end of first quarter of 2010. This trial marks an important milestone in ORMD-0801 safety testing, assessing the first indication of ORMD-0801 on a large group of volunteers over an extended treatment period.
Oramed Pharmaceuticals Inc. financial resources
ORMP Competitors
| Company | Last | Change | |
| No competitor information is available for ORMP. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | ORMP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 10.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ORMP |
||
ORMP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
Read article
Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Read article
Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
Read article
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Read article
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Read article
Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
Oramed Pharmaceuticals to Present at OneMedPlace Finance Forum in San Francisco, California
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Read article